Listen to the latest Hemonc news
from international experts
Advancing immunotherapy for solid tumors
Immunotherapy has the potential to treat all types of cancer, making it a highly lucrative area of research. Since the first FDA-approved immunotherapy for bladder cancer in 1990, the Bacillus Calmette-Guérin cancer vaccine, many more agents have arrived on the scene. A challenge in this field is not only finding the right therapeutic targets and optimizing efficacy, but also managing the immune-related side effects. In this podcast, our experts explore the use of immunotherapies in solid tumors.
Date: 23rd November 2018